Institutional Biosafety Program

It is the policy of the Icahn School of Medicine at Mount Sinai that employees conduct research, clinical, and teaching activities involving biohazardous materials in a safe manner in order to protect the research community, visitors, and public community.

The Institutional Biosafety Program identifies biological safety practices, procedures, facility construction, and operational standards for the safe handling and use of biohazardous materials for research, clinical, and teaching activities at the School. The Program applies to all academic faculty, staff, visiting scientists, students, public visitors, volunteers, and contract personnel located on the campus or any locations where the School has management control of specific biohazardous materials.

The Icahn School of Medicine at Mount Sinai Institutional Biosafety Committee (IBC) monitors all laboratory activities involving:

Recombinant DNA and synthetic DNA molecules as required by the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, April 2019, (the NIH Guidelines)
Biological agents classified as Risk Group 2, 3, and 4 in the NIH Guidelines
Research involving Select Agents and Toxins that are subject to the Select Agent Regulations

Workforce Health Updates

Workforce Health requires employees to schedule appointments for completing occupational health compliance (i.e., influenza immunization, Purified Protein Derivatives/QuantiFERON-TB Gold Tests/Tuberculosis screening), Annual Health Assessments, return to work clearances, and work-related injuries and follow ups.